The objective of this study was to assess the impact of manufacturing-scale, freeze-thaw conditions on aggregation and subvisible particle formation of a monoclonal antibody solution (mAb-A; IgG1) using a small-scale model.
W. Aaron Pruett
Advertisement
W. Aaron Pruett is drug product process engineer, Novavax.
Articles by W. Aaron Pruett
Advertisement
Latest Updated Articles
Impact of Manufacturing-Scale Freeze-Thaw Conditions on a mAb SolutionPublished: February 1st 2017 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
